Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.68 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.68 |
| ▸ | PDE5A | O76074 | 13/20 | 0.59 |
| ▸ | GUCY1A1 | Q02108 | 4/20 | 0.49 |
| ▸ | GUCY1B1 | Q02153 | 4/20 | 0.49 |
| ▸ | BUB1 | O43683 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5473538 | 0.92 | KCNH2 (0.80) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL5477000 | 0.90 | KCNH2 (0.84) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL6222071 | 0.89 | ADORA3 (0.68) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL175083 | 0.85 | ADORA3 (0.62) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL9913936 | 0.85 | ADORA3 (0.62) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL14362950 | 0.83 | ADORA3 (0.71) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL14362945 | 0.83 | ADORA3 (0.64) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL7835258 | 0.83 | ADORA3 (0.65) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL255860 | 0.82 | KCNH2 (0.64) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL5477476 | 0.82 | ADORA3 (0.67) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1506193-B9 | CARBAMATE-SUBSTITUTED PYRAZOLOPYRIDINES | ADVERIO PHARMA GMBH (DE) | 2026-02-18 | — | — | EP | disclosed |
| EP-1506193-B3 | CARBAMATE-SUBSTITUTED PYRAZOLOPYRIDINES | ADVERIO PHARMA GMBH (DE) | 2025-12-03 | — | — | EP | disclosed |
| US-20070225299-A1 | Novel Combination Containing a Stimulator of Soluble Guanylate Cyclase and a Lipid-Lowering Substance | BAYER HEALTHCARE AG (DE) | 2007-09-27 | — | — | US | disclosed |
| EP-1506193-B1 | CARBAMATE-SUBSTITUTED PYRAZOLOPYRIDINES | BAYER HEALTHCARE AG (DE) | 2006-06-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225299-A1 | Novel Combination Containing a Stimulator of Soluble Guanylate Cyclase and a Lipid-Lowering Substance | GUCY1A2, GUCY1B2, GUCY1B1 | ADORA3 928/4885KCNH2 2335/4885PDE5A 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.